Eyepoint Pharmaceuticals (NASDAQ: EYPT) — Company Overview, News & Financial Data
Eyepoint Pharmaceuticals specializes in therapeutics for eye diseases, focusing on sustained-release drug delivery innovations.
Eyepoint Pharmaceuticals
Eyepoint Pharmaceuticals (NASDAQ:EYPT) focuses on developing and commercializing therapeutics for eye diseases. Specializing in sustained release drug delivery products, this company is dedicated to advancing treatments for serious eye disorders. Their project portfolio includes innovative technologies aimed at improving the lives of patients with chronic eye conditions. Eyepoint Pharmaceuticals is actively engaged in research, development, and commercialization stages to bring its unique products to market. The company's objectives are centered on achieving excellence in eye care, expanding their product offerings, and reaching a broader patient population.
Snapshot
Operations
Products and/or services of Eyepoint Pharmaceuticals
- YUTIQ - A treatment for chronic non-infectious uveitis affecting the posterior segment of the eye.
- DEXYCU - An FDA-approved intraocular product for the treatment of postoperative inflammation.
- ILUVIEN - A micro-insert for diabetic macular edema, licensed to Alimera Sciences in certain markets.
- EYP-1901 - A potential treatment for wet age-related macular degeneration, utilizing a bioerodible Durasert technology.
- Development of treatments for ocular diseases using Durasert and bioerodible sustained release drug delivery platforms.
- Partnerships for leveraging its drug delivery technologies in ophthalmology and other therapeutic areas.
Eyepoint Pharmaceuticals executive team
- Jay S. DukerPresident, CEO & Director
- George O. ElstonExecutive VP & CFO
- Ramiro RibeiroChief Medical Officer
- Marcia Sellos-MouraChief Scientific Officer
- Ron I. HonigChief Legal Officer & Company Secretary
- Jennifer LeonardChief People Officer & Senior VP of IT
- David Scott JonesSenior Vice President
- Isabelle LefebvreChief Regulatory Officer
- Michael J. MaciocioChief Manufacturing Officer
- Michael CampbellChief Commercial Officer
Key financials
Reported results for Eyepoint Pharmaceuticals, in USD.
- Market cap
- 32.8M
- Revenue (TTM)
- 2.8M
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 31.4M | -243.4M | -232M | |
| 43.3M | -145.9M | -130.9M | |
| 46M | -75.1M | -70.8M | |
| 41.4M | -99.6M | -102.3M |